-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:GWO公布的基本盈利为12.39亿加元,同比增长20%;基本每股收益为1.37加元,同比增长23%。基本净资产收益率达到19.1%,同比增长190个基点,首次达到公司19%的中期目标。所有四个运营部门的基本盈利均实现两位数增长,主要得益于市场升值带来的手续费收入增加、资本和风险解决方案业务新业务量的持续增长以及保险体验的改善。美国业务表现强劲,基本盈利达3.14亿美元,同比增长23%;Empower Retirement的净计划资金流入达53亿美元。公司保持了稳健的资本状况,LICAT比率为129%,环比增长100个基点,基本资本生成率超过80%。股东价值回报依然强劲,本季度回购了5.67亿加元的股票,季度股息增长10%至每股0.67加元。客户总资产达3.3万亿加元,效率比率提升220个基点至54.5%。
Related Articles
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.